Asparlas Calaspargase Pegol-mknl

Fact of Medicine

  • Brand Name: Asparlas
  • Innovator Brand Name: Asparlas
  • API: Calaspargase pegol – mknl
  • Packaging: 1 Vial (Per Box)
  • Strength: 3750 units per 5ml
  • Manufacturer Name: Servier Pharmaceuticals
Get Price
Categories: ,


Uses of medication: Asparlas (Calaspargase pegol – mknl) is used as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL (Acute Lymphoblastic Leukemia) in the young adult (aged 1 month to 21 years) and pediatric patients.

Dosage: The recommended asparlas dose is 2,500 units/m2, which should be administered intravenously not more frequently than every 3 weeks.

Treatment Reactions: The most commonly reported asparlas side effects include:

  • Elevated transaminase
  • Bilirubin increased
  • Pancreatitis
  • Abnormal clotting studies

Warnings and precautions

  • The asparlas uses should be avoided in patients with the history of serious hypersensitivity reactions, including anaphylaxis, to pegylated L-asparaginase therapy.
  • Patients receiving treatment with calaspargase 3750 injection should seek medical assistance in case they experience excessive thirst or any increase in the frequency of urination.
  • Patients with asparlas 3750 injection should contact their doctor promptly if jaundice, severe nausea or vomiting, or easy bruising or bleeding occurs.
  • Women with childbearing potential and receiving asparlas injection should avoid becoming pregnant.
  • Due to the potential for adverse reactions in a breastfed baby, lactating women should avoid breastfeeding while on calaspargase pegol injection and for 3 months after the final dose.

More Info.

Storage: Asparlas should be stored at 2°C to 8°C (36°F to 46°F) in the original carton in order to protect from the light. Avoid shaking or freezing it. Unopened vials may be stored at temperature 15°C to 25°C (59°F to 77°F) for not more than 48 hours.

Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship ASPARLAS at the global level as per the need of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the ASPARLAS Injections.

Buying Procedure: In order to buy ASPARLAS, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: along with your Valid ID Proof, Prescription Letter and Medical Reports.

Conclusion: Asparlas (Calaspargase pegol – mknl) is safe and effective in the treatment of Acute Lymphoblastic Leukemia in the pediatric and young adult patients aged 1 month to 21 years, with manageable safety profile

Commonly Asked Questions

What does Asparlas contain as an active substance?

The medication Asparlas specifically contains the active substance Calaspargase pegol – mknl.

From which class of drug Calaspargase pegol belongs?

Calaspargase pegol basically belongs to a class of drugs named antineoplastics.

How does Calaspargase pegol act?

As an enzyme, calaspargase pegol-mknl mainly interferes with the natural substances crucial for cancer cell growth. It acts in order to kill or stop the growth of cancer cells.

How much does asparlas cost?

The asparlas price in India may vary depending on the wholesaler/pharmacy you visit. Cost for the asparlas 750 units/mL is around 18,27,576 INR for a supply of 5 milliliters.

Where can I get Calaspargase pegol at the best price?

In order to get the best calaspargase pegol price, always buy this medication from that Pharmaceutical Wholesaler Company which is WHO-GDP and ISO certified.

Can I get Calaspargase pegol (Asparlas) even if I am not based in India?

The Indian Pharma helps patients in accessing or importing Calaspargase pegol (Asparlas), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

Send your inquiry to find Asparlas (Calaspargase Pegol-mknl Injection) in UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia, Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand. China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.